ContraFect Announces Dr. Roger J. Pomerantz, Chief Executive Officer and Chairman, Invited as Keynote Speaker and Presenter in Maxim’s Infectious Disease Virtual Conference April 21, 2020
ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update March 18, 2020
ContraFect to Present at FDA Workshop on Advancing Animal Models for Antibacterial Drug Development March 4, 2020
ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis February 24, 2020
ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology February 3, 2020
